From: Role and targeting of anaplastic lymphoma kinase in cancer
Drug | Targets | Phase of clinical development | References |
---|---|---|---|
Crizotinib | ALK c-MET ROS1 | Indication worldwide for therapy of NSCLC harbouring ALK gene rearrangement in first and second line | • Shaw AT, et al. NEJM 2013 [32] • Solomon BJ, et al. NEJM 2014 [33] |
Alectinib | ALK, including ALK secondary mutationsRET | - Approval from FDA (December 2015) and EMA (February 2017) in second line therapy of NSCLC harbouring ALK gene after progression to crizotinib - FDA granted fast approval in first line setting based on results of phase II and III clinical trials | • Larkins E, et al. CCR 2016 [52] • Shaw AT, et al. Lancet Oncol 2016 [56] • Hida T, et al. Lancet 2017 [59] • Peters S, et al. NEJM 2017 [60] |
Ceritinib | ALK, including ALK secondary mutations IGF-1R ROS1 STK22D | - Recent fast approval from FDA in second line therapy of NSCLC harbouring ALK gene after progression to crizotinib (May 2017) based on results of phase II clinical trials | • Crinò L, et al. JCO 2016 [48] • Shaw AT, et al. JTO 2016 [47] |
Brigatinib | ALK, including ALK secondary mutations ROS1 EGFR NTRK1 | - Recent fast approval from FDA in second line therapy of NSCLC harbouring ALK gene after progression to crizotinib (April 2017) based on results of phase II clinical trials | • Markham A, et al. Drugs 2017 [61] |
Lorlatanib | ALK and ROS1, including all known their mutant forms | Ongoing phase III trials in NSCLC first line versus crizotinib | • ClinicalTrials.gov, NCT03052608 |
Entrectinib | ALK, Including ALK secondary mutations NTRK1, 2, and 3 ROS1 | Ongoing phase II basket trial STARTRK-2 (NCT02568267) | • Drilon A, et al. Cancer Discovery 2017 [63] |